FDA Approved: SOLIQUA 100/33 — Original Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

FDA approved SOLIQUA 100/33, a fixed-dose combination of insulin glargine and lixisenatide, marking the original approval of this product. It is indicated for t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SOLIQUA 100/33 (INSULIN GLARGINE AND LIXISENATIDE)

Snippet

ORIG AP for SOLIQUA 100/33 (INSULIN GLARGINE AND LIXISENATIDE)